Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
1. A method of treating hepatic steatosis in a patient comprising orally administering an effective amount of an ileal brake composition in an oral dosage form comprising an ileal brake compound wherein at least 50% by weight of the ileal brake compound administered to said patient is released in the ileum of the patient.
2. The method according to claim 1 wherein the ileal brake composition lowers one or more of; elevated insulin resistance; elevated liver enzymes ALT and AST; and triglycerides.
3. The method according to claim 2 wherein the lowering one or more of; elevated insulin resistance; elevated liver enzymes ALT and AST; and triglycerides, mimics the effects of Roux-en-Y gastric bypass surgery (RYGB).
4. The method according to claim 1 wherein said patient is infected with hepatitis B or C and said ileal brake compound is coadministered with an antiviral agent.
5. The method according to claim 4 wherein said patient is infected with hepatitis C.
6. The method according to claim 4 wherein viral counts in said patient are effectively lowered, and the health of steatotic cells in the liver of said patient, are improved.
7. The method according to claim 4 wherein said antiviral agent is ribavirin, pegylated interferon, boceprevir, daclatasvir, asunapavir, INX-189, FV-100, NM 283, VX-950 (telaprevir), SCH 50304, TMC435, VX-500, BX-813, SCH503034, R1626, ITMN-191 (R7227), R7128, PF-868554, TT033, CGH-759, GI 5005, MK-7009, SIRNA-034, MK-0608, A-837093, GS 9190, GS 9256, GS 9451, GS 5885, GS 6620, GS 9620, GS9669, ACH-1095, ACH-2928, GSK625433, TG4040 (MVA-HCV), A-831, F351, NS5A, NS4B, ANA598, A-689, GNI-104, IDX102, ADX184, ALS-2200, ALS-2158, BI 201335, BI 207127, BIT-225, BIT-8020, GL59728, GL60667, PSI-938, PSI-7977, PSI-7851, SCY-635, TLR9 Agonist, PHX1766, SP-30 or a mixture thereof.
8. The method according to claim 4 , wherein the antiviral agent is an effective amount of pegylated interferon in combination with ribavirin.
9. The method according to claim 4 , wherein the antiviral agent is pegylated interferon and/or ribavirin, further combined with boceprevir in a dosage of at least 800 mg three times daily.
10. The method according to claim 4 , wherein the antiviral agent is pegylated interferon and/or ribavirin, further combined with telaprevir in a dosage of at least 750 mg three times daily.
11. The method according to claim 4 , wherein the antiviral agent is an effective amount of daclatasvir, asunaprevir or a mixture thereof, optionally in further combination with an effective amount of pegylated interferon and/or ribavirin.
12. The method according to claim 4 , wherein the antiviral agent is an effective amount of daclatasvir alone or in combination with an effective amount of pegylated interferon and/or ribavirin.
13. The method according to claim 4 , wherein the antiviral agent is an effective amount of asunaprevir alone or in combination with an effective amount of pegylated interferon and/or ribavirin.
14. The method according to claim 4 , wherein the antiviral agent is an effective amount of INX-189, alone or in combination with an effective amount of pegylated interferon and/or ribavirin.
15. The method according to claim 4 , wherein the antiviral agent is an effective amount of FV-100 alone or in combination with an effective amount of pegylated interferon and/or ribavirin.
16. A method for producing an oral ileal brake compound composition which comprises the steps of:
1) coating the ileal brake compound with a material which has a pH dissolution or time delayed profile that delays the release in vivo of the majority of the ileal brake compound until the dosage form reaches the subject's ileum; and
2) coating the ileal brake compound inside a microparticle to form a population of microparticles, said microparticles releasing the compound at pH values specific to the coating within the range of about 7.0 to about 7.8.
17. The method according to claim 1 wherein a majority of the ileal brake compound is released from the dosage form when the dosage form reaches the patient's ileum, whereupon the ileal brake composition may either activate or re-activate the L-cells of the ileum and thereby produce all of the chemical and physiological characteristics of an activated ileal brake in a manner similar to RYGB surgery.
18. The method according to claim 17 , wherein the ileal brake compound microparticles comprise a core which are coated by an enteric coating, wherein the coating thickness controls the dissolution of said ileal brake compound from said microparticles, thereby delaying release of the majority of the ileal brake compound until the microparticles reach the patient's ileum.